Silver Book Fact

Cost of pneumonia vaccine

Addition of PCV13 (13-valent pneumococcal conjugate vaccine) to previously recommended pneumococcal polysaccharide vaccine for immunocompromised adults cost $70,937 per quality adjusted life year compared to no vaccine.

Smith K, Nowalk M, Raymund M, Zimmerman R. Cost-Effectiveness of Pneumococcal Conjugate Vaccination in Immunocompromised Adults. Vaccine. 2013; 31(37): 3950-6. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3742552/

Reference

Title
Cost-Effectiveness of Pneumococcal Conjugate Vaccination in Immunocompromised Adults
Publication
Vaccine
Publication Date
2013
Authors
Smith K, Nowalk M, Raymund M, Zimmerman R
Volume & Issue
Volume 31, Issue 37
Pages
3950-6
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Use of shingles vaccines significantly reduced disease burden
    Use of a live attenuated VZV (varicella-zoster vaccine) in a randomized trial reduced the burden of illness from shingles by 61.1% and the incidence of postherpetic neuralgia (PHN) by 66.5%.  
  • Life years saved from infectious disease eradication
    Infectious disease eradication in the U.S. led to the following annual life years saved (LYS): 5,811,852 for measles 42,702 for tetanus 212,690 for polio 1,685,740 for smallpox  
  • Cost of pneumonia vaccine
    Addition of PCV13 (13-valent pneumococcal conjugate vaccine) to previously recommended pneumococcal polysaccharide vaccine for immunocompromised adults cost $70,937 per quality adjusted life year compared to no vaccine.  
  • Cost savings from immunization
    Every dollar spent on immunization saves $6.30 in direct medical costs – a total savings of $10.5 billion. When including indirect costs such as lost days of work, disability,…  
  • Vaccines in development 2013
    Biopharmaceutical research companies are developing 271 vaccines for infectious diseases, cancer, neurological disorders, allergies, and other diseases.